Hims & Hers Health Inc. Aktie News

Hims & Hers is a Strong Buy, as shares appear historically cheap due to temporary margin compression and regulatory concerns. HIMS's recurring revenue model, 70%+ gross margins, and rapid subscriber growth underpin a compelling long-term growth thesis despite recent profit volatility. Significant investments in global expansion, new product lines, and vertical integration are expected to drive ...

Hims & Hers Health Inc  (NYSE:HIMS) shares are up 3.4% to trade at $30.60 at last glance.

Revenue grew nearly 50% year over year in Q3 2025 to ~$600 million, with ARPU rising and free cash flow reaching $79 million. Gross margin declined to ~74% from high-70s levels due to GLP-1 shipping cadence changes, price cuts, and facility expansion inefficiencies. Operating cash flow approached $150 million in the quarter, with over $1 billion in cash and investments supporting reinvestment a...

Amazon could be on the cusp of an artificial intelligence (AI)-driven boom in profitability. Hims & Hers Health stock is pricey, but the company's massive growth potential makes up for it.

Hims & Hers stock has nosedived in the past few months. It has dived by over 56% from its highest point in July last year and is now hovering at its lowest level since April.

Hims & Hers Health remains a speculative buy for aggressive growth investors, driven by its pivot toward precision medicine and AI-enabled healthcare. Recent volatility stems from regulatory risks, the Novo Nordisk partnership breakup, and shifting GLP-1 compounding regulations impacting revenue and investor sentiment. HIMS's valuation sits between telehealth and AI/genomics peers, with substan...

Hims & Hers is down 50% from all-time highs amid fading momentum in their compounded GLP-1 offerings, while new growth vectors are yet to translate into revenue acceleration. Sequential revenue deceleration, margin contraction, and lowered FY25 guidance have pressured Hims stock, but management maintains ambitious 2030 targets. New growth vectors—testosterone, menopause, Labs, and international...

Hims & Hers Health is significantly undervalued, with the market underestimating its growth potential and international expansion opportunities. Geographical and product expansion, vertical integration, and a unique personalized offering position HIMS to regain historical growth rates by 2026 and beyond. Management targets substantial margin expansion, aiming for adjusted EBITDA margins of at l...